<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html dir="ltr" xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml">
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>

<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<!-- 
	This website is powered by TYPO3 - inspiring people to share!
	TYPO3 is a free open source Content Management Framework initially created by Kasper Skaarhoj and licensed under GNU/GPL.
	TYPO3 is copyright 1998-2015 of Kasper Skaarhoj. Extensions are copyright of their respective owners.
	Information and contribution at http://typo3.org/
-->



<title>INHN: Lehmann Collection 1 : Charles E. Cahn’s interview of Heinz E. Lehmann</title>
<meta name="generator" content="TYPO3 4.5 CMS" />

<link rel="stylesheet" type="text/css" href="IMAGES/STYLESHEET_9B1E31873F2366.CSS?1645000983" media="all" />



<script src="IMAGES/JAVASCRIPT_93077BB238F3E1.JS?1645000982" type="text/javascript"></script>


<link href="IMAGES/LAYOUT_3COL_STANDARD.CSS" rel="stylesheet" type="text/css" /><!--[if lte IE 7]><link href="fileadmin/styles/patches/../01_layouts_basics/css/patches/patch_3col_standard.css" rel="stylesheet" type="text/css" /><![endif]-->
<meta name="DC.title" content="Lehmann Collection 1 : Charles E. Cahn’s interview of Heinz E. Lehmann" />
<meta name="description" content="INHN" />
<meta name="DC.Description" content="INHN" />
<meta name="keywords" content="International Network for the History of Neuropsychopharmacology" />
<meta name="DC.Subject" content="International Network for the History of Neuropsychopharmacology" />
<meta name="copyright" content="Copyright INHN 2012-14" />
<meta name="DC.Rights" content="Copyright INHN 2012-14" />
<meta http-equiv="content-language" content="en" />
<meta name="DC.Language" scheme="NISOZ39.50" content="en" />
<link rev="made" href="mailto:inhn@inhn.org" />
<meta http-equiv="reply-to" content="inhn@inhn.org" />
<meta name="author" content="Gregers Wegener" />
<meta name="DC.Creator" content="Gregers Wegener" />
<meta name="rating" content="General" />
<meta name="date" content="2020-08-18T14:43:20+00:00" />
<meta name="DC.date" content="2020-08-18T14:43:20+00:00" />
<meta name="robots" content="index,follow" />
<meta name="revisit-after" content="7" />
<link rel="start" href="INDEX681A.HTM?id=1" />
<link rel="up" href="INDEX768D.HTM?id=2359" />
<link rel="next" href="INDEXAF7B.HTM?id=3591" />
<link rel="prev" href="INDEXE728.HTM?id=3566" />
<link rel="canonical" href="INDEX0343.HTM?id=3583" />



</head>
<body id="pageUID-3583">


<div id="page_margins">
	<div id="page">
		<div id="header"><div class="tx-macinasearchbox-pi1">
		
<form action="https://inhn.org/index.php?id=5&amp;L=0" method="post" name="searchform" id="searchform">
<input name="tx_indexedsearch[sword]" type="text" value="Enter search word..." onclick="this.value=''" onblur="this.value='Enter search word...'" /><br />
<input type="hidden" name="tx_indexedsearch[_sections]" value="0" />
<input type="hidden" name="tx_indexedsearch[pointer]" value="0" />
<input type="hidden" name="tx_indexedsearch[ext]" value="0" />
<input type="hidden" name="tx_indexedsearch[lang]" value="0" />
</form>

	</div>
	<div id="topnav"><a class="skip" href="#navigation" title="Direkt zur Navigation springen">Zur Navigation springen</a><span class="hideme">.</span><a class="skip" href="#content" title="Direkt zum Content springen">Zum Content springen</a><span class="hideme">.</span><a href="INDEX3A9F.HTM?id=6" target="_self">Sitemap</a>&nbsp;&#124;&nbsp;<a href="INDEXD61C.HTM?id=5" target="_self">Search</a>&nbsp;&#124;&nbsp;<a href="INDEX65E4.HTM?id=kontakt" target="_self">Contact</a>&nbsp;&#124;&nbsp;<a href="INDEXB7B8.HTM?id=204" target="_self">About INHN</a></div><a href="INDEX2999.HTM?id=202"><img class="headImg1" src="IMAGES/COMPANY_LOGO.GIF" alt="" title="Home" width="598" height="100" /></a></div>
		<div id="nav"><a id="navigation" name="navigation"></a><div id="nav_main" class="hlist"><ul><li id="current"><a href="INDEX2999.HTM?id=202" target="_self"><span>Home</span></a></li><li><a href="INDEX7EFD.HTM?id=479" target="_self"><span>Dictionary</span></a></li><li><a href="INDEX3E5C.HTM?id=374" target="_self"><span>Drugs</span></a></li><li><a href="INDEXDBB1.HTM?id=565" target="_self"><span>Photos</span></a></li><li><a href="INDEXD919.HTM?id=342" target="_self"><span>Profiles</span></a></li><li><a href="INDEXAF9F.HTM?id=355" target="_self"><span>Controversies</span></a></li><li><a href="INDEXD122.HTM?id=641" target="_self"><span>Discoveries</span></a></li><li><a href="INDEX1F24.HTM?id=384" target="_self"><span>Books</span></a></li><li><a href="INDEX3958.HTM?id=467" target="_self"><span>Biographies</span></a></li><li><a href="INDEX677F.HTM?id=642" target="_self"><span>Perspectives</span></a></li><li><a href="INDEX8C00.HTM?id=343" target="_self"><span>Archives</span></a></li><li><a href="INDEX06CB.HTM?id=368" target="_self"><span>Ebooks</span></a></li><li><a href="INDEXA1F1.HTM?id=1755" target="_self"><span>Collated</span></a></li><li><a href="INDEXDF25.HTM?id=4128" target="_self"><span>Multilingual Project</span></a></li><li><a href="INDEXABE4.HTM?id=3884" target="_self"><span>INHN Publisher</span></a></li></ul></div></div>
		<div id="main">
			<div id="teaser" class="clearfix"><div class="rootline">You are here: <a href="INDEX2999.HTM?id=202" target="_self">Home</a>&nbsp;/&nbsp;<a href="INDEX3F39.HTM?id=1016" target="_self">Central Office (Cordoba Unit)</a>&nbsp;/&nbsp;<a href="INDEXC279.HTM?id=1659" target="_self">EDUCATION</a>&nbsp;/&nbsp;<a href="INDEX768D.HTM?id=2359" target="_self">Thomas A. Ban Neuropsychopharmacology in Historical Perspective - Education in the Field in the Post-Neuropsychopharmacology Era</a>&nbsp;/&nbsp;Lehmann Collection 1 : Charles E. Cahn’s interview of Heinz E. Lehmann</div><div class="langMenu"><div class="tx-srlanguagemenu-pi1">
		
	</div>
	</div></div>
			<div id="col1">
				<div id="col1_content" class="clearfix">
					<ul id="submenu"><li id="title">Home</li><li><a href="INDEXB7B8.HTM?id=204" target="_self">About INHN</a><span class="hidden">.</span></li><li><a href="INDEXC104.HTM?id=854" target="_self">Towards education</a><span class="hidden">.</span></li><li><a href="INDEX3F39.HTM?id=1016" target="_self">Central Office (Cordoba Unit)</a><span class="hidden">.</span><ul><li><a href="INDEXEC89.HTM?id=1265" target="_self">Carlos Morra: Central Office</a></li><li><a href="INDEXF6AE.HTM?id=1234" target="_self">Administrative Unit by Leon S. Morra</a></li><li><a href="INDEXA81B.HTM?id=1233" target="_self">Carlos Morra: Chronological list of essential publications</a></li><li><a href="INDEXFC5C.HTM?id=3915" target="_self">Carlos Morra: Guide for Authors</a></li><li><a href="INDEX7A09.HTM?id=1123" target="_self">Thomas A. Ban: Recommended additions</a></li><li><a href="INDEX15CB.HTM?id=1587" target="_self">ADMINISTRATIVE UNIT</a><span class="hidden">.</span></li><li><a href="INDEXC279.HTM?id=1659" target="_self">EDUCATION</a><span class="hidden">.</span><ul><li><a href="INDEX768D.HTM?id=2359" target="_self">Thomas A. Ban Neuropsychopharmacology in Historical Perspective - Education in the Field in the Post-Neuropsychopharmacology Era</a><span class="hidden">.</span><ul><li><a href="INDEX114E.HTM?id=2360" target="_self">Bulletin 1: Educational Series 2. Jacques-Joseph Moreau de Tours.</a></li><li><a href="INDEX9E33.HTM?id=2367" target="_self">Bulletin 2 : Educational Series 2.Prologue</a></li><li><a href="INDEX1338.HTM?id=2375" target="_self">Bulletin 3 : Educational Series 2.  Vignette 1 Overview of the series: An Oral History of Neuropsychopharmacology</a></li><li><a href="INDEXF2B4.HTM?id=2385" target="_self">Bulletin 4 : Educational Series 2. Chapter 1: John Dalton’s atomic theory and drugs in psychiatry in the 19th century</a></li><li><a href="INDEXAEB2.HTM?id=2388" target="_self">Educational Series 2. Bulletin 5. Vignette 2: Sedatives in the second part of the 19th century</a></li><li><a href="INDEX8D36.HTM?id=2399" target="_self">Educational Series 2. Bulletin 6, Chapter 2: From William Cullen’s “neuroses” to Johann Christian Reil’s “psychiaterie”</a></li><li><a href="INDEX05B0.HTM?id=2404" target="_self">Educational Series 2. Bulletin 7, Vignette 3: Classifications of insanity in the late 18th and early 19th century</a></li><li><a href="INDEX525B.HTM?id=2414" target="_self">Educational Series 2. Bulletin 8, Chapter 3: Substances with an effect on consciousness</a></li><li><a href="INDEXA355.HTM?id=2422" target="_self">Educational Series 2. Bulletin 9 Vignette 4 :The isolation of morphine</a></li><li><a href="INDEX3BEE.HTM?id=2431" target="_self">Bulletin 10 : Reflexes of the brain</a></li><li><a href="INDEX8D24_2.HTM?id=2438" target="_self">Bulletin 11 : Sechenov’s re-evaluation of mental faculties and the brain</a></li><li><a href="INDEX796C.HTM?id=2451" target="_self">Bulletin 12 : Bayle’s discovery and the re-evaluation of the concept of dementia</a></li><li><a href="INDEX76A9_2.HTM?id=2458" target="_self">Bulletin 13 : Louis Sokoloff Autobiography – Regional mapping and imaging of the nervous system</a></li><li><a href="INDEXD4A9_2.HTM?id=2463" target="_self">Bulletin 14 : Joseph J. Schildkraut: Autobiography – The catecholamine hypothesis before and thereafter</a></li><li><a href="INDEXD5AC.HTM?id=2474" target="_self">Bulletin 15 : Alfred Pletscher Autobiography – On the Eve of the Birth of the Neurotransmitter Era in Biological Psychiatry</a></li><li><a href="INDEX6102.HTM?id=2483" target="_self">Bulletin 16 : Leo E. Hollister’s Interview of Julius Axelrod – The Uptake of Neurotransmitters and Psychoactive Drugs</a></li><li><a href="INDEXD4EC.HTM?id=2491" target="_self">Bulletin 17 : Thomas A. Ban’s Interview of Irwin J. Kopin – Metabolic disposition of catecholamines</a></li><li><a href="INDEXD604.HTM?id=2506" target="_self">Bulletin 18 : Thomas A. Ban’s Interview of Philip B. Bradley – Recording Electrical Activity from Cerebral Cortex and Subcortical Structures in Conscious Cats</a></li><li><a href="INDEXCD11.HTM?id=2521" target="_self">Bulletin 19 : From Conditioning and Psychiatry to Psychopharmacology*</a></li><li><a href="INDEX036F.HTM?id=2524" target="_self">Bulletin 20 : Conditioning and Psychiatry</a></li><li><a href="INDEXA67B.HTM?id=2533" target="_self">Bulletin 21 : Psychopharmacology</a></li><li><a href="INDEXA9EE_2.HTM?id=2543" target="_self">Bulletin 22 : Physiological patterns: A diagnostic test procedure based on the conditional reflex method</a></li><li><a href="INDEX8191.HTM?id=2551" target="_self">Bulletin 23 : Clinical pharmacology of psychotropic drugs</a></li><li><a href="INDEX0FE8.HTM?id=2562" target="_self">Bulletin 24 : Methodology and pitfalls in clinical testing of psychopharmacological drugs</a></li><li><a href="INDEX840B.HTM?id=2570" target="_self">Bulletin 25 : Toxicity and Adverse Reaction Studies with Neuroleptics and Antidepressants</a></li><li><a href="INDEX739E.HTM?id=2578" target="_self">Bulletin 26 : The effect of phenothiazines on the electrocardiogram</a></li><li><a href="INDEXF797.HTM?id=2586" target="_self">Bulletin 27 : Skin pigmentation, a rare side effect of chlorpromazine</a></li><li><a href="INDEX825E.HTM?id=2594" target="_self">Bulletin 28 : Ernst Feuchtersleben’s separation of psychosis from neurosis</a></li><li><a href="INDEXDC51.HTM?id=2603" target="_self">Bulletin 29 : Wilhelm Griesinger and Unitary Psychosis (Einheitpsychose)</a></li><li><a href="INDEX0C60.HTM?id=2612" target="_self">Bulletin 30 : Towards Neuropsychopharmacology in 1957</a></li><li><a href="INDEX76BD.HTM?id=2621" target="_self">Bulletin 31 : Fifty years CINP</a></li><li><a href="INDEX2103.HTM?id=2630" target="_self">Bulletin 32 : Fifty years ACNP</a></li><li><a href="INDEX6B55.HTM?id=2638" target="_self">Bulletin 33 : Starting Up (Volume One): 1. The Interviews</a></li><li><a href="INDEXEDEF.HTM?id=2647" target="_self">Bulletin 34 : Starting Up (Volume One): 2. Psychiatry</a></li><li><a href="INDEX22AE.HTM?id=2656" target="_self">Bulletin 35 : Starting Up (Volume One): 3. Drugs</a></li><li><a href="INDEXC051.HTM?id=2665" target="_self">Bulletin 36 : Starting Up (Volume One): 4. Pharmacology</a></li><li><a href="INDEX3552.HTM?id=2674" target="_self">Bulletin 37 : Starting Up (Volume One):  5. Interviewees</a></li><li><a href="INDEXBF4E.HTM?id=2683" target="_self">Bulletin 38 : Neurophysiology (Volume Two): 1. Early Development</a></li><li><a href="INDEXF887.HTM?id=2692" target="_self">Bulletin 39 : Neurophysiology (Volume Two): 2. Interviewees Contributions</a></li><li><a href="INDEX7741.HTM?id=2700" target="_self">Bulletin 40 : Neuropharmacology (Volume Three): 1. Neurotransmitters</a></li><li><a href="INDEXC58E.HTM?id=2708" target="_self">Bulletin 41 : Neuropharmacology (Volume Three): 2. Psychotropic drugs</a></li><li><a href="INDEX917B.HTM?id=2717" target="_self">Bulletin 42 : Neuropharmacology (Volume Three): 3a. Contributions of Interviewees</a></li><li><a href="INDEXBBC9.HTM?id=2726" target="_self">Bulletin 43 : Neuropharmacology (Volume Three): 3b. Contributions of Interviewees</a></li><li><a href="INDEX5AFC.HTM?id=2734" target="_self">Bulletin 44 : Psychopharmacology (Volume Four): 1. Clinical methodology</a></li><li><a href="INDEX5441.HTM?id=2751" target="_self">Bulletin 45 : Psychopharmacology (Volume Four): 2a. Contributions of Interviewees</a></li><li><a href="INDEXBB17.HTM?id=2760" target="_self">Bulletin 46 : Psychopharmacology (Volume Four): 2b. Contributions of Interviewees</a></li><li><a href="INDEX9F22.HTM?id=2761" target="_self">Bulletin 47 : Psychopharmacology (Volume Four): 2c. Contributions of Interviewees</a></li><li><a href="INDEXEFAA.HTM?id=2770" target="_self">Bulletin 48 : Neuropsychopharmacology (Volume Five): 1.Model Psychosis</a></li><li><a href="INDEX0571.HTM?id=2778" target="_self">Bulletin 49 : Neuropsychopharmacology (Volume Five): 2. Psychotoxic metabolites</a></li><li><a href="INDEX5740.HTM?id=2787" target="_self">Bulletin 50 : Neuropsychopharmacology (Volume Five): 3. Psychopharmacology of Schizophrenia; Psychopharmacology of Depression; Endocrine Measures</a></li><li><a href="INDEX47D5.HTM?id=2795" target="_self">Bulletin 51 : Neuropsychopharmacology (Volume Five): 4a. Contributions of Interviewees</a></li><li><a href="INDEXEE5A_2.HTM?id=2801" target="_self">Bulletin 52 : Neuropsychopharmacology (Volume Five): 4b. Contributions of Interviewees</a></li><li><a href="INDEX59FE.HTM?id=2810" target="_self">Bulletin 53 : Neuropsychopharmacology (Volume Five): 4c. Contributions of Interviewees</a></li><li><a href="INDEX0E71.HTM?id=2820" target="_self">Bulletin 54 : Addiction (Volume Six): 1. Addiction Psychiatry</a></li><li><a href="INDEXAE91.HTM?id=2829" target="_self">Bulletin 55 : Addiction (Volume Six): 2. Substances of abuse</a></li><li><a href="INDEX9B7D.HTM?id=2837" target="_self">Bulletin 56 : Addiction (Volume Six): 3. Conditioning and addiction</a></li><li><a href="INDEX0047_2.HTM?id=2846" target="_self">Bulletin 57 : Addiction (Volume Six): 4a. Contributions of interviewees</a></li><li><a href="INDEX44BA.HTM?id=2854" target="_self">Bulletin 58 : Addiction (Volume Six): 4b. Contributions of interviewees.</a></li><li><a href="INDEX0F23.HTM?id=2863" target="_self">Bulletin 59 : Special Areas (Volume Seven): 1. Child Psychiatry</a></li><li><a href="INDEXAA86.HTM?id=2871" target="_self">Bulletin 60 : Special Areas (Volume Seven): 2. Geriatric Psychiatry</a></li><li><a href="INDEX9ECC.HTM?id=2883" target="_self">Bulletin 61 : Special Areas (Volume Seven): 3. Psychiatric diagnosis</a></li><li><a href="INDEX1EC3.HTM?id=2892" target="_self">Bulletin 62 : Special Areas (Volume Seven): 4. Pharmacokinetics</a></li><li><a href="INDEXBAEC.HTM?id=2902" target="_self">Bulletin 63 : Special Areas (Volume Seven): 5a. Contributions of Interviewees.</a></li><li><a href="INDEX38B7.HTM?id=2921" target="_self">Bulletin 64 : Special Areas (Volume Seven): 5b. Contributions of Interviewees</a></li><li><a href="INDEX54DB.HTM?id=2938" target="_self">Bulletin 65 : Special Areas (Volume Seven): 5c. Contributions of Interviewees</a></li><li><a href="INDEX5194.HTM?id=2952" target="_self">Bulletin 66 : Diverse Topics (Volume Eight): 1. Regulation, Ethics, Marketing and Education, Conflict of Interest</a></li><li><a href="INDEXF272.HTM?id=2960" target="_self">Bulletin 67 : Diverse Topics (Volume Eight): 2a. Interviewees Contributions</a></li><li><a href="INDEXCAF4.HTM?id=2969" target="_self">Bulletin 68 : Diverse Topics (Volume Eight): 2b. Interviewees Contributions</a></li><li><a href="INDEX8272.HTM?id=2979" target="_self">Bulletin 69 : Update (Volume Nine): 1. Pharmacogenetics and Genetics and Neuropsychopharmacology</a></li><li><a href="INDEXBD8C.HTM?id=2988" target="_self">Bulletin 70 : Update (Volume Nine): 2. Psychopathology and Nosology</a></li><li><a href="INDEX2A75.HTM?id=3004" target="_self">Bulletin 71 : Update (Volume Nine): 3a. Interviewee’s Contributions</a></li><li><a href="INDEX48C2.HTM?id=3021" target="_self">Bulletin 72 : Update (Volume 9) 3b. Interviewees contributions</a></li><li><a href="INDEX616E.HTM?id=3030" target="_self">Bulletin 73 : Volume 10. Postscript</a></li><li><a href="INDEX1D4A.HTM?id=3036" target="_self">Bulletin 74 : An Overview of Developments in Psychopharmacology and Neuropsychopharmacology</a></li><li><a href="INDEX2F0A.HTM?id=3048" target="_self">Bulletin 75 : The confounding of education with marketing</a></li><li><a href="INDEX1E85.HTM?id=3055" target="_self">Bulletin 76 : Towards a genetic era in neuropsychopharmacology</a></li><li><a href="INDEX5072.HTM?id=3062" target="_self">Bulletin 77 : The CODE System</a></li><li><a href="INDEXBB3A.HTM?id=3071" target="_self">Bulletin 78 : Nosologic Homotyping</a></li><li><a href="INDEX5262.HTM?id=3085" target="_self">Collated Bulletin 1: RDoC in Historical Perspective.</a></li><li><a href="INDEX8197.HTM?id=3094" target="_self">Collated Bulletin 2 : Neuropsychopharmacology and the Forgotten Language of Psychiatry</a></li><li><a href="INDEXCB60.HTM?id=3103" target="_self">Collated Bulletin 3 : In Historical Perspective: Peralta, Cuesta and their associate’s findings on the highest familiality of Leonhard’s Classification in Polynosologic Study</a></li><li><a href="INDEX55BE.HTM?id=3111" target="_self">Collated Bulletin 4: Thomas A. Ban: The Birth of a Medical Discipline: Psychiatry</a></li><li><a href="INDEX1328.HTM?id=3124" target="_self">Collated Bulletin 5: Thomas A. Ban: Conflict of Interest in Neuropsychopharmacology. Marketing vs. Education.</a></li><li><a href="INDEX9A64.HTM?id=3130" target="_self">Collated Bulletin 6: Edward Shorter: The QT interval and the Mellaril story</a></li><li><a href="INDEXC9E3.HTM?id=3143" target="_self">Collated Bulletin 7 : Thomas A. Ban: The Wernicke – Kleist – Leonhard Tradition with Special Reference to Mania, Melancholia and Manic – Depressive Psychosis</a><span class="hidden">.</span></li><li><a href="INDEX1124.HTM?id=3152" target="_self">Collated Bulletin 8 : Thomas A. Ban: The Birth of Drug Industry and Drugs with An Effect On Behavior</a></li><li><a href="INDEX1A41.HTM?id=3164" target="_self">Collated Bulletin 9 : Thomas A. Ban: From Melancholia to Depression</a></li><li><a href="INDEX4A53.HTM?id=3170" target="_self">Collated Bulletin 10 : Thomas A. Ban: The Year 1845</a></li><li><a href="INDEX4878.HTM?id=3182" target="_self">Collated Bulletin 11 : Joseph Knoll: The discovery of monoamine oxidase (MAO) enzymes</a><span class="hidden">.</span></li><li><a href="INDEX13FE.HTM?id=3200" target="_self">Collated Bulletin 12 : Samuel Gershon: Events and Memories</a></li><li><a href="INDEXBAD0.HTM?id=3287" target="_self">Collated Bulletin 13 : Paul Devenyi: Addictions are not treatable diseases and Pharmacotherapy of addiction not a success story.</a></li><li><a href="INDEX80F0.HTM?id=3297" target="_self">Collated Bulletin 14 : Janos Radó: The use of modern antidiuretic agents in the treatment of permanent lithium-induced nephrogenic diabetes insipidus</a></li><li><a href="INDEX7FB2.HTM?id=3305" target="_self">Collated Bulletin 15 : Per Bech:  Clinical Psychometrics</a></li><li><a href="INDEX2912.HTM?id=3312" target="_self">Collated Bulletin 16 : Martin M. Katz: Onset of clinical effects of antidepressants</a></li><li><a href="INDEX412B.HTM?id=3321" target="_self">Collated Bulletin 17 : Martin M. Katz: Depression and Drugs, a monograph  and Multivantaged vs Conventional Assessment, an essay</a></li><li><a href="INDEXB116.HTM?id=3330" target="_self">Collated Bulletin 18 : Per Bech:  Measurement-based care in mental disorders (New York: Springer; 2016) Foreword and Review</a></li><li><a href="INDEX8100.HTM?id=3338" target="_self">Collated Bulletin 19 : Donald F. Klein and John Davis: Diagnosis and Drug Treatment of Mental Disorders and Thomas A. Ban: Psychopharmacology in 1969</a></li><li><a href="INDEX7B0A.HTM?id=3345" target="_self">Collated Bulletin 20 : Thomas A. Ban: Schizophrenia in the Early 1970s</a></li><li><a href="INDEXAF2B.HTM?id=3355" target="_self">Collated Bulletin 21 : Thomas A. Ban, Marcelo Cetkovich-Bakmas, Ernst Franzek and Hector Warnes: Carl Wernicke’s “elementary symptoms” and “sejunction hypothesis”</a></li><li><a href="INDEXE783.HTM?id=3374" target="_self">Collated Bulletin 22 : Martin M. Katz: Clinical Trials of Antidepressants: How Changing the Model Can Uncover New, More Effective Molecules</a></li><li><a href="INDEX4AF0.HTM?id=3393" target="_self">Collated Bulletin 23 : Joseph Knoll: From the Theory of Active Reflexes to a Neurochemical Concept of Innate and Acquired Drive</a></li><li><a href="INDEXC922.HTM?id=3401" target="_self">Collated Bulletin 24 : Ildiko Miklya: The  History of Selegiline (-) Deprenyl the First Selective Inhibitor of B-Type Monoamine Oxidase and the First Synthetic Catecholaminergic Enhancer Substance</a></li><li><a href="INDEX5549.HTM?id=3411" target="_self">Collated Bulletin 25 : Joseph Knoll: The Discovery of the Enhancer Regulation in the Mammalian Brain and the Development of the Synthetic Enhancer Substances</a></li><li><a href="INDEXBEF3.HTM?id=3421" target="_self">Collated Bulletin 26 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology: Julius Axelrod, Frank Ayd, Frank Berger, Hans Berger and Hermann Blaschko</a></li><li><a href="INDEXDEB4.HTM?id=3428" target="_self">Collated Bulletin 27 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology. Charles Bradley, Philip B. Bradley, Bernard B. Brodie, John Cade and John Delay</a></li><li><a href="INDEX65AD.HTM?id=3436" target="_self">Collated Bulletin 28 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology. Edmundo Fischer, W. Horsley Gantt, Turan M. Itil, Hitoshi Itoh and Paul Kielholz</a></li><li><a href="INDEX9D53.HTM?id=3446" target="_self">Collated Bulletin 29 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology. Nathan S. Kline, Roland Kuhn, Heinz E. Lehmann, Laszlo Meduna and Dionisio Nieto Gomez</a></li><li><a href="INDEX05ED.HTM?id=3454" target="_self">Collated Bulletin 30 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology. Alfred Pletscher, Juri Saarma, Sydney Spector, Leo Sternbach, Edward Trautner and Joseph Wo</a></li><li><a href="INDEX51CB.HTM?id=3464" target="_self">Collated Bulletin 31 : Thomas A. Ban: Lithium. 1. Discovery of its therapeutic effect in psychiatry. Johan Schioldann, William T. Hammond and Carl Lange</a></li><li><a href="INDEX7AE6.HTM?id=3471" target="_self">Collated Bulletin 32 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective. 2. Introduction into treatment in psychiatry. Samuel Gershon: Profiles of John Cade and Edward Trautner</a></li><li><a href="INDEX9492.HTM?id=3479" target="_self">Collated Bulletin 33 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective. 3. Early Years. Samuel Gershon: First-Hand Accounts</a></li><li><a href="INDEX5A82.HTM?id=3489" target="_self">Collated Bulletin 34 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective</a></li><li><a href="INDEXBC82.HTM?id=3497" target="_self">Collated Bulletin 35 : Thomas A. Ban: Lithium. 4. Controversy. Barry Blackwell vs Paul Grof and Jules Angst</a></li><li><a href="INDEXE7C3.HTM?id=3506" target="_self">Collated Bulletin 36 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective 5. Turning point. Paul Grof and Johan Schioldann</a></li><li><a href="INDEXF857.HTM?id=3514" target="_self">Collated Bulletin 37 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective 6. Action. Janusz Rybakowski</a></li><li><a href="INDEX6E77.HTM?id=3523" target="_self">Collated Bulletin 38 : Thomas A. Ban: 7.  Diagnosis</a></li><li><a href="INDEX680B.HTM?id=3532" target="_self">Collated Bulletin 39 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective Dedication and Preface</a></li><li><a href="INDEX516F.HTM?id=3541" target="_self">Collated Bulletin 40 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective.</a></li><li><a href="INDEX1901.HTM?id=3550" target="_self">Collated Bulletin 41 : Peter R. Martin. Volume 1. Recollections of the History of Neuropsychopharmacology Through Interviews Conducted by Thomas A. Ban</a></li><li><a href="INDEXCA36.HTM?id=3558" target="_self">Collated Bulletin 42 : Peter R. Martin. Volume 2. Recollections of the History of Neuropsychopharmacology Through Interviews Conducted by Leo E. Hollister</a></li><li><a href="INDEXE728.HTM?id=3566" target="_self">Collated Bulletin 43 : Peter R. Martin. Volume 2. Recollections of the History of Neuropsychopharmacology Through Interviews Conducted by William E. Bunney, Jr.</a></li><li><strong>Lehmann Collection 1 : Charles E. Cahn’s interview of Heinz E. Lehmann</strong></li><li><a href="INDEXAF7B.HTM?id=3591" target="_self">Lehmann Collection 2 : William E. Bunney’s interview of Heinz E. Lehmann</a></li><li><a href="INDEXC461.HTM?id=3599" target="_self">Lehmann Collection 3 : Heinz Edgar Lehmann by Barry Blackwell</a></li><li><a href="INDEXC5D4.HTM?id=3607" target="_self">Lehmann Collection 4 : Heinz Lehmann and Douglas Hospital by Charles C. Cahn</a></li><li><a href="INDEXEC5F.HTM?id=3616" target="_self">Lehmann Collection 5 : Heinz Edgar Lehmann’s research profile by Antonio E. Nardi.</a></li><li><a href="INDEXDB89.HTM?id=3624" target="_self">Lehmann Collection 6 : Heinz E. Lehmann by Edward Shorter.</a></li><li><a href="INDEXB434.HTM?id=3633" target="_self">Lehmann Collection 7 : Per Bech’s comment on Heinz E. Lehmann*</a></li><li><a href="INDEX1767.HTM?id=3641" target="_self">Lehmann Collection 8 : Paul Grof’s comment on Heinz E. Lehmann. A few personal recollections</a></li><li><a href="INDEX7BD1.HTM?id=3650" target="_self">Lehmann Collection 9 : Irwin J. Kopin’s comment on Heinz E. Lehmann.</a></li><li><a href="INDEXAE03.HTM?id=3661" target="_self">Lehmann Collection 10 : Mary and Philip Seeman's comment</a></li><li><a href="INDEXDDD3.HTM?id=3680" target="_self">Lehmann Collection 11 : A Tribute to Heinz Edgar Lehmann by Hector Warnes.</a></li><li><a href="INDEX42F1.HTM?id=3689" target="_self">Lehmann Collection 12 : Heinz Edgar Lehmann:  Publication</a></li><li><a href="INDEX8FD0.HTM?id=3698" target="_self">Lehmann Collection 13 :  Thomas A. Ban: My Personal Notes on Heinz Lehmann</a></li><li><a href="INDEXC658.HTM?id=3707" target="_self">Lehmann Collection 14 : Thomas A. Ban: Heinz E. Lehmann and Psychopharmacology</a></li><li><a href="INDEXB918.HTM?id=3717" target="_self">Lehmann Collection 15 : Thomas A. Ban: Towards a clinical methodology for neuropsychological research</a></li><li><a href="INDEXF57D.HTM?id=3726" target="_self">Lehmann Collection 16 : Heinz Edgar Lehmann</a></li><li><a href="INDEX1FC5.HTM?id=3734" target="_self">Lehmann Collection 17 : Heinz E. Lehmann: What is wrong with getting old?</a></li><li><a href="INDEX1A9C.HTM?id=3743" target="_self">Lehmann Collection 18 : Heinz E. Lehmann: Dreaming about Mental Health</a></li><li><a href="INDEXDC72.HTM?id=3753" target="_self">Lehmann Collection 19: Heinz E. Lehmann: Alcoholism, aggression and androgen function. Discussion of paper by Jack Mendelson</a></li><li><a href="INDEX7FE1.HTM?id=3761" target="_self">Lehmann Collection 20: Heinz E. Lehmann: Perspectives in Psychosurgery</a></li><li><a href="INDEX6E26.HTM?id=3770" target="_self">Lehmann Collection 21 : Heinz E. Lehmann: Discussion of the paper by Prof. P. Pichot:  The Treatment of Depression</a></li><li><a href="INDEX2F04.HTM?id=3778" target="_self">Lehmann Collection 22 : Heinz E. Lehmann: Harlem Valley Revisited</a></li><li><a href="INDEX8D36_2.HTM?id=3788" target="_self">Lehmann Collection 23 : Heinz E. Lehmann: Chlorpromazine: The Story of Phenothiazine Derivatives, Their Clinical Indications, the Incidence and Management of Untoward Effects and a Proposed Rational for Its Action</a></li><li><a href="INDEXC42B.HTM?id=3796" target="_self">Lehmann Collection 24 : Heinz E. Lehmann: The Anatomy of Research Funding</a></li><li><a href="INDEX7DC1.HTM?id=3804" target="_self">Lehmann Collection 25 : Program of Academic morning in honor of Dr. Heinz Lehmann</a></li><li><a href="INDEX212A.HTM?id=3814" target="_self">Lehmann Collection 26 : Heinz E. Lehmann: Types and Characteristics of Objective Measures of Psychopathology</a></li><li><a href="INDEX40D0.HTM?id=3877" target="_self">Classification of Functional Psychoses 1 : Preface and Recommended Reading</a></li><li><a href="INDEXF49C.HTM?id=3888" target="_self">Classification of Functional Psychoses 2 : Introduction</a></li><li><a href="INDEX12CF.HTM?id=3896" target="_self">Classification of Functional Psychoses 3 : ICD-9 and DSM-III</a></li><li><a href="INDEX93EE.HTM?id=3906" target="_self">Classification of Functional Psychoses 4: Classification of Mental Disorders and Psychopharmacology – Diagnostic Criteria for Research</a></li><li><a href="INDEX0CDC.HTM?id=3914" target="_self">Classification of Functional Psychoses 5: The KDK Budapest</a></li><li><a href="INDEX6A56.HTM?id=3923" target="_self">Classification of Functional Psychoses 6: One- and Two-Dimensional Diagnoses</a></li><li><a href="INDEX44FB.HTM?id=3933" target="_self">Classification of Functional Psychoses 7: Delusional Development and Delusional Psychoses</a></li><li><a href="INDEXA244.HTM?id=3942" target="_self">Classification of Functional Psychoses 8: Bayle’s Unitary Concept of Psychosis and Endogenous Psychoses</a></li><li><a href="INDEX76A8.HTM?id=3952" target="_self">Classification of Functional Psychoses 9: Affective Psychosis</a></li><li><a href="INDEXF554.HTM?id=3960" target="_self">Classification of Functional Psychoses 10: Empirical and Pragmatic Classifications of Depression</a></li><li><a href="INDEXB28B.HTM?id=3969" target="_self">Classification of Functional Psychoses 11: Schizophrenic Psychoses</a></li><li><a href="INDEXEE78.HTM?id=3977" target="_self">Classification of Functional Psychoses 12: Cycloid Psychoses</a></li><li><a href="INDEX79BA.HTM?id=3985" target="_self">Classification of Functional Psychoses 13: Conclusions</a></li><li><a href="INDEXFDAB.HTM?id=3994" target="_self">Classification of Functional Psychoses 14: References</a></li><li><a href="INDEXF3F8.HTM?id=4011" target="_self">Delcir da Costa’s comment on collating document</a></li><li><a href="INDEXFAD4.HTM?id=4030" target="_self">Dementia Differential Diagnosis 1991 : Contents</a></li><li><a href="INDEX05BB.HTM?id=4042" target="_self">Dementia Differential Diagnosis 1991 : Conceptual Development</a></li><li><a href="INDEXA331.HTM?id=4051" target="_self">Dementia Differential Diagnosis 1991 : Dementing Illnesses</a></li><li><a href="INDEXDEF5.HTM?id=4059" target="_self">Dementia Differential Diagnosis 1991 : Modified Concept</a></li><li><a href="INDEX4686.HTM?id=4068" target="_self">Dementia Differential Diagnosis 1991 : Diagnosing of Dementing Illness</a></li><li><a href="INDEXED54.HTM?id=4077" target="_self">Dementia Differential Diagnosis 1991 : References</a></li><li><a href="INDEX0D43.HTM?id=4132" target="_self">Methodology pitfalls of clinical testing of psychopharmaceutical</a></li><li><a href="INDEX9601.HTM?id=4140" target="_self">Mental health (Psychiatry) and pharmaceuticals in a historical perspective</a></li><li><a href="INDEX114D.HTM?id=4150" target="_self">Nosology in the teaching of psychiatry. Introduction</a></li><li><a href="INDEX4294.HTM?id=4158" target="_self">Towards a clinical methodology for neuropsychopharmacological research</a></li><li><a href="INDEXD825.HTM?id=4176" target="_self">Selective Drugs Versus Heterogeneous Diagnoses. Towards a New Methodology in Psychopharmacologic Research</a></li></ul></li><li><a href="INDEXC4F2.HTM?id=2324" target="_self">Per Bech: Members of the International Committee for the Prevention and Treatment of Depression in the mid-1980s</a></li><li><a href="INDEXC2D5.HTM?id=2299" target="_self">Per Bech and Wolfgang Rutz: The Story of the International Committee for the Prevention and Treatment of Depression</a></li><li><a href="INDEX9256.HTM?id=2371" target="_self">Peter R. Martin: Historical Dictionary of Addiction</a><span class="hidden">.</span></li><li><a href="INDEX527D.HTM?id=2648" target="_self">Amara McLaughlin-Harris: The Legal History of Psychoactive Drugs</a><span class="hidden">.</span></li><li><a href="INDEXFB23.HTM?id=2184" target="_self">Carlos Morra: An Educational Model in Psychiatry</a><span class="hidden">.</span></li><li><a href="INDEX9A07.HTM?id=2428" target="_self">Carlos Morra and Ernst Franzek: Psychopathological Symptoms</a><span class="hidden">.</span></li><li><a href="INDEX0793.HTM?id=3533" target="_self">Carlos Morra and Mateo Kreiker: Psychopathology</a><span class="hidden">.</span></li></ul></li></ul></li><li><a href="INDEX4710.HTM?id=3072" target="_self">INHN Publisher</a><span class="hidden">.</span></li><li><a href="INDEX7227.HTM?id=1114" target="_self">Programs</a><span class="hidden">.</span></li><li><a href="INDEXEAE0.HTM?id=1266" target="_self">Courses</a><span class="hidden">.</span></li><li><a href="INDEX86F6.HTM?id=1296" target="_self">Interviews</a><span class="hidden">.</span></li><li><a href="INDEXEF79.HTM?id=410" target="_self">Copyright Policy</a></li><li><a href="INDEX756E.HTM?id=437" target="_self">How to cite INHN</a></li><li><a href="INDEXCF6F.HTM?id=3373" target="_self">Website Table of Contents</a></li><li><a href="INDEXD254.HTM?id=2343" target="_self">Last Uploads</a></li></ul>
					
					<div class="textBelowMenu"><!--TYPO3SEARCH_begin--><!--TYPO3SEARCH_end--></div>
				</div>
			</div>
			<div id="col2">
				<div id="col2_content" class="clearfix"><!--TYPO3SEARCH_begin--><!--TYPO3SEARCH_end--></div>
			</div>
			<div id="col3">
			  <a id="content" name="content"></a>
				<div id="col3_content" class="clearfix">
					<div class="floatbox"><!--TYPO3SEARCH_begin--><!--DMAILER_SECTION_BOUNDARY_--><div id="c5379" class="csc-default"><h1><h1 style="FONT-SIZE: 23.25px; FONT-FAMILY: &quot;Trebuchet MS&quot;, Verdana, Helvetica, Arial, sans-serif; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: bold; COLOR: rgb(102,102,102); PADDING-BOTTOM: 0px; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; PADDING-RIGHT: 0px; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"><span style="FONT-SIZE: 23.25px; FONT-WEIGHT: normal; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; MARGIN: 0px; PADDING-RIGHT: 0px">Thomas A. Ban<br style="FONT-SIZE: 23.26px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; MARGIN: 0px; PADDING-RIGHT: 0px" />Neuropsychopharmacology in Historical Perspective.</span></h1><h1 style="FONT-SIZE: 23.25px; FONT-FAMILY: &quot;Trebuchet MS&quot;, Verdana, Helvetica, Arial, sans-serif; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: bold; COLOR: rgb(102,102,102); PADDING-BOTTOM: 0px; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; PADDING-RIGHT: 0px; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"><span style="FONT-SIZE: 23.25px; FONT-WEIGHT: normal; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; MARGIN: 0px; PADDING-RIGHT: 0px">Lehmann Collection 1</span></h1></h1>
<h1>&nbsp;</h1>
<h1>Charles E. Cahn’s interview of Heinz E. Lehmann* </h1>
<p>&nbsp;</p>
<p>Dr . Cahn : &nbsp;Today I am interviewing Dr. Heinz Lehmann. To start with, can you tell us how you became interested in psychiatry? </p>
<p>Dr. Lehmann: Well, I was an adolescent, about 14 years old, and I had suddenly developed difficulties in learning, achieving in school, to the point where I could not do any homework at al1, and things looked pretty grim. Now, in retrospect, I think I would make the diagnosis that I probably had a depression. Nowadays we a lot about adolescent depression. In those days, there was no such thing - adolescents and children had no depression. So there was no diagnosis and no treatment and no way out. Apparently, I wasn`t able to do my high school work, and my parents were told to let me learn a trade instead; but they engaged a tutor for me. He was a student, a university student, who at that time was very interested in Freud' s writings, and he was very psychologically-minded. He came, he did my homework with me often for me. He came every day for about a year and I got out of my depression. At the time that happened, I was very much interested in psychological writings - in fact, between the ages of 14 and 15 1 read &nbsp;everything Freud had written at that time. I still remember quite a few passages - where they were, on which page, and so on. So that gave me a mind-set for psychological thinking and influenced me as far as Freud was concerned for the rest of my life and my career.</p>
<p>But I also was always very interested in physics and chemistry and all natural sciences, so when I came to make a decision of what I was going to do later on - my father was a physician - I chose to go into medicine. But I immediately made up my mind that I would become a psychiatrist, which, from a 15 year old at that time, sounded awful to my surgeon father and everybody else. They all said: well, if you go into medicine, you cannot know what you are going to do in the end; besides, psychiatry? There's no future in it! True, in psychiatry there was no treatment then; nobody could make a proper diagnosis, the whole thing was the least promising specialty in medicine. But I insisted that I would go into psychiatry later on and so I did. I also always remained very much interested in physical sciences. It followed that I was, from the beginning, interested in the biological aspect of psychiatry, and, of course, also in the psychological and psychoanalytical, psychodynamic aspects, because of the early imprinting. </p>
<p>This combined approach has pretty well been my whole perspective in psychiatry all along; the biological and the psychodynamic aspects having about equal weight. </p>
<p>Dr. C.: So this started out in the country where you were borne. Would you 1ike to tell us a bit about your moves? </p>
<p>Dr. L.: I was born in Germany, and I finished my university studies there, in Berlin. I also studied in Vienna, in Marburg and Freiburg, as one did then in Europe – one went to as many universities as one's father's pocket book could afford. Then Hitler arrived and I had to leave Germany. I came to Canada, to this hospital where we are now, Douglas Hospital. I walked in here on the fourth or fifth day after my arrival in Montreal, asking whether I could get a job. I did get a job, just before the war, so several of the other doctors and many other staff people had to leave. I had a caseload of about 600 patients and had to look after them alone, with one nurse, and a lot of untrained attendants, as they were called then, and it didn't leave me much time. I started at 8:30 in the morning and I finished at 1 or 2 at night. That was my postgraduate training in psychiatry. I never had the time, or the taste, to go for formal postgraduate studies in psychiatry. I learned it here, without much apprenticeship and formal teaching, but by “total immersion” one might say. </p>
<p>Dr. C.: Things began to change after the war, when what important events happened?</p>
<p>Dr. L.: After the war there was a kind of revolution in psychiatry in North America. The snake pit-like conditions of mental hospitals underwent a change, the mental hospital environment was much improved. Within about eight to ten years, the psychotropic drugs were discovered: to start with, antipsychotic drugs in France, the phenothiazines. I was one of the first to read those French reports. Because my wife is French Canadian we speak French at home, and so I could read the French medical literature; I became very intrigued by one or two of the first papers by Delay and Deniker from France, on a new drug that apparently produced peculiar affects. I was so much intrigued that I decided I would try these drugs out here. The next day I cornered the first psychiatric resident I met and asked him whether he would work with me on this new drug, which seemed to be almost incredibly effective in conditions for which nothing else would work. He joined me in the research - it was Dr. Hanrahan - and within three months we had treated more than 70 patients with the new drug, incidentally, without any grant money. I did not even have to ask my superintendent whether I could do the study I just did it. There was no informed consent concept at that time. Of course we didn't have any extra staff, it all had to be folded into the daily work, not even secretarial help. Within three or four months we had the first paper ready - that was the first paper in the English language on antipsychotic or neuroleptic drugs.</p>
<p>Dr. C.: That was chlorpromazine, or largactil, as it was named by the company.</p>
<p>Dr. L.: Yes, that was chlorpromazine. From then on it followed that I became rather absorbed in psychopharmacology. I was actually urged by the NIMH to apply for a grant. It sounds strange today, but in those days in the study groups of the NIMH, where I was also invited to work, we sometimes did not know what to do with our money; I remember one time when we had a million dollars in Washington we had to spend before the end of the fiscal year, and we did not know what to do with it. So, in the next ten or twenty years I was doing a great deal of clinical trials work, and there is probably hardly any drug, either antidepressant or antipsychotic or anxiolytic, that I did not work with in clinical trials at that time.</p>
<p>Dr. C.: Can we just talk for a moment about imipramine which was the first major antidepressant drug?</p>
<p>Dr. L.: Well, there again, I think ours was one of the first papers in English - ours, that is yours and mine - we both were coauthors. I had read about Kuhn's work who was the one who discovered the antidepressant effects of imipramine. I had read about his work in a Swiss journal.</p>
<p>Dr. C.: In German?</p>
<p>Dr. L.: In German, yes. The other one on chlorpromazine was in French. Of course so many, if not most, of the real breakthroughs in psychiatry came from Europe until quite recently, and so also the antidepressants and a little later the benzodiazepines, the anxiolytics were added to all the clinical trials we were doing, most of it here in this Hospital in Montreal.</p>
<p>Dr. C.: Who were some of the people who influenced you the most?</p>
<p>Dr. L.: As I said before, Freud is one of them. Afterwards, as a student in my first year of university I was supposed to study only medicine, but I was also studying philosophy. I became interested, and definitely came under the influence of the existential philosophers, especially Heidegger - I was in his seminars in Freiburg on St. Augustine, Kant, Hegel and Husserl, and in seminars of other philosophers; so the existential aspects and the epistemological problems of psychiatry and of making a diagnosis, as well as making experimental studies - all this has always been very important to me. The existential aspect of philosophy also influenced my psychiatric approach to patients, so that I have really three perspectives for each patient: an existential one, a psychodynamic one, and a biological one. </p>
<p>Dr. C.: Were there any Canadian psychiatrists who made a difference to you?</p>
<p>Dr. L.: Well I was and I am still reading very widely in psychiatry. I spend on an average two hours every day just reading psychiatric literature. In that way, every psychiatrist who publishes had or has some influence on me.</p>
<p>Dr. C.: No one stands out in particular?</p>
<p>Dr. L.: No.</p>
<p>Dr. C.: What about American psychiatrists?</p>
<p>Dr. L.: No. It is strange - I have no hero, except Jaspers and Kraepelin, the cornerstones of modern European psychiatry, one might say. And then, of course, Freud. But I have never taken postgraduate training either, as 1 mentioned before, so there is no particular person whom I would consider a mentor, although I have of course met many of the outstanding psychiatrists in North America and in Europe, but none of them has had any particular influence on my psychiatry.</p>
<p>Dr. C.: What do you think have been the most important developments in psychiatry in the last ten years?</p>
<p>Dr. L.: I know what most people would say and what I am expected to and do tell my students, with qualifications: the most important recent developments are obviously the neuroscientific discoveries and the technological advances, the imagery, the sort of thing like the PET and the MRI, the quantified EEG that can make us actually see an image when people think, where they are thinking in the brain, or whatever physical processes take place in the brain while they are thinking, what it&nbsp; looks like on graphs and false color images. But while that is a great progress, it is to me also a danger to psychiatry, because, as I see it, the psychological understanding and the psychiatric treatment of a patient is not really helped very much by these technological breakthroughs . I still have to see how the PET and MRI - as they have existed now for fifteen years or so - have helped in the treatment or even in the understanding of patients. Neuroscientifically, we can explain molecular processes much better today because molecular biology and discoveries in neurochemistry are helping us to develop more specific and often more helpful drugs. And the molecular biological breakthroughs in genetics they are remarkable - but again, as a psychiatrist, somebody who is treating, not just trying to explain, mental illness, there is not anything that can be done with our genetic discoveries at this point, and perhaps not for the next ten or twenty years - at least, not anything that we have not been doing for many years, like genetic counselling. </p>
<p>Dr. C. : Coming back to your own contributions, I know you are a modest person, but would you like to tell us about what you think were your most important contributions to psychiatry?</p>
<p>Dr. L.: Well, the demonstration that psychotropic drugs, such as chlorpromazine, for instance, are actually effective, so effective that there remains no doubt about it, even for the sturdiest psychoanalyst. Eventually they all had to admit that there is a physical substrate to, say, schizophrenia and bipolar or manic-depressive disorder, because certain physical substances, drugs, definitely are helpful in treating these disorders. Before that, until the early 1950s, it was archaic and very unsophisticated almost simplistic - to think that anything physical could be done in the treatment of schizophrenia. It had been tried for so many years, decades, and nothing had ever helped, so one would have to understand schizophrenia on psychodynamic terms, and the only rational intervention was psychoanalytical or psychodynamic treatment. Well, the fact that I was able to demonstrate, with others, that physical substances can profoundly change the course of schizophrenia and other psychoses made it quite clear that there was a biological substrate as well as psychodynamic factors involved in their causation for that matter probably both in equal measure.</p>
<p>Dr. C.: In other words, there is no major mental disorder which does not have some kind of physical or chemical basis?</p>
<p>Dr. L.: Oh, I wouldn’t say that.</p>
<p>Dr. C.: No?</p>
<p>Dr. L.: No. For that matter, every thought has a physical basis , of course. If we would not breathe oxygen we could not think. But where does the reductionism stop? It can go down to the single cell that is activated, or fires at certain rhythms, the gating of ions in the neuron, and so on, in the brain, but that does not give us any idea - and probably, in my conviction, never will, tell us anything about the particular thought in which the firing of that cell is involved. All we can say is that as long as we are alive we must be biologically functioning, based on physical substrates. But what has that to do with human psychology?</p>
<p>Dr. C.: In the future of psychiatry as you see it now what would be the most important developments?</p>
<p>Dr. L.: I am often asked what I think is the next big breakthrough, and sometimes, not always, I say that I am expecting no new drug or no new physical discovery or treatment to be a really new breakthrough, but I am hoping for the media to produce some sort of a psychological revolution in the public area, just as the sexual revolution came about through the media, although it had been something that had been unthinkable ten years before. So I hope that eventually there will be a psychological revolution, meaning that people will really begin to think and act seriously regarding psychological problems, such as, how to raise children, how not to beat them up - or how to structure ones value system away from money and power, which are the fundamental values for every red-blooded American and Canadian today. Change our value system to constructive social interactions and to creativity and consider money merely as a necessary thing and power a thrilling, but dangerous pleasure, but nothing to particularly strive for or spend time with. That will be a long time off, but once we get there I suppose it will have a great influence on peace in the world.</p>
<p>If only everyone knew how not to treat children, how to be better parents, we would probably, in my opinion, reduce all mental disorders by 25 to 30%. Other more immediate progress will, I hope, take place when we begin to realize that there is no polarity between either the biological aspect of psychiatry or the psychodynamic, and that the two are welded together. Now, I know there is the biopsychosocial model: everybody talks about and everybody says this is their model, but very few people really respect it; people give lip service to it by saying &quot;oh yes, of course.” Is there is a biological substrate - we are physicians, we have to know a lot about physiology and we have to use drugs - but they are really passionately involved only in psychodynamics; or the other pole where psychopharmacologists will say, &quot;oh, of course, I know there are psychological aspects to be considered, placebo effects, and dynamics and so on - but they are really completely involved only in the biological and psychopharmacological neuroscience aspects. If the two would really come together and get equal weight, in teaching as well as in practice, then I think we will really make progress in psychiatry. Right now we are on a dangerous course, as I see it, because it takes endless hours for psychiatric residents to study neuropharmacology and neuroscience which they will never quite master because they have not got a Ph.D. But dabbling in it takes a lot of time, much too much time, away from being with patients, understanding patients, dealing with patients, talking with them, listening to them. Also, it is too easy to take cook book recipes, simulating psychopharmacology; and we are, of course, seduced by the fact that when we have a PET scan we have something that other physicians and other specialties have, namely, some objective graphs, some objective evidence. In psychiatry we have always been hungry for that sort of thing and often feel under-privileged because we do not even have any sphygmomanometers or thermometers, to objectively evaluate our patients. Instead of feeling under-privileged we should feel privileged that psychiatry is the one specialty in medicine where we can and must transcend the biological machines and molecular assemblies.</p>
<p>Dr. C.: Is there anything else you would like to say?</p>
<p>Dr. L.: No, I just wish that my hopes will be fulfilled.</p>
<p>Dr. C.: That concludes the interview with Dr. Heinz Lehmann, whom I consider a “psychiatrist for all seasons.” Thank you very much.</p>
<p>&nbsp;</p>
<p>*The interview took place in Montreal, Quebec, in the late 1980s. </p>
<p>&nbsp;</p>
<p>August 20, 2020</p></div><!--DMAILER_SECTION_BOUNDARY_END--><!--TYPO3SEARCH_end--></div>
				</div>
				<div id="ie_clearing">&nbsp;</div>
			</div>
		</div>
		<div id="footer">&copy; INHN 2012-2022 ::: INHN Central Office  · Av. Sagrada Familia Esq Nazaret · Córdoba, Córdoba X5000 · Argentina  ::: email: inhn@inhn.org</div>
	</div>
</div>





<script src="IMAGES/URCHIN.JS" type="text/javascript">
</script>
<script type="text/javascript">
_uacct = "UA-39727086-1";
urchinTracker();
</script>
</body>
</html>